Amylyx Pharmaceuticals’ (AMLX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Amylyx Pharmaceuticals (NASDAQ:AMLXFree Report) in a report issued on Wednesday, Benzinga reports. They currently have a $8.00 price target on the stock.

Separately, Mizuho lowered their target price on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a neutral rating for the company in a research report on Tuesday, May 14th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Amylyx Pharmaceuticals currently has a consensus rating of Hold and a consensus target price of $24.80.

Read Our Latest Research Report on Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Trading Up 25.5 %

NASDAQ AMLX opened at $2.07 on Wednesday. The stock has a market cap of $140.78 million, a PE ratio of -1.93 and a beta of -0.64. Amylyx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $25.48. The stock’s 50 day moving average is $1.79 and its 200 day moving average is $7.41.

Amylyx Pharmaceuticals (NASDAQ:AMLXGet Free Report) last posted its earnings results on Friday, May 10th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.70). The firm had revenue of $88.64 million for the quarter, compared to the consensus estimate of $113.26 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a positive return on equity of 4.14%. During the same quarter in the prior year, the company posted $0.02 earnings per share. On average, analysts forecast that Amylyx Pharmaceuticals will post -1.36 EPS for the current fiscal year.

Institutional Trading of Amylyx Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Premier Path Wealth Partners LLC purchased a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at $298,000. Franklin Resources Inc. increased its stake in Amylyx Pharmaceuticals by 114.4% in the fourth quarter. Franklin Resources Inc. now owns 1,325,001 shares of the company’s stock worth $19,504,000 after purchasing an additional 707,134 shares during the period. Sectoral Asset Management Inc. increased its stake in Amylyx Pharmaceuticals by 14.1% in the fourth quarter. Sectoral Asset Management Inc. now owns 84,055 shares of the company’s stock worth $1,237,000 after purchasing an additional 10,400 shares during the period. Graham Capital Management L.P. increased its stake in Amylyx Pharmaceuticals by 84.1% in the third quarter. Graham Capital Management L.P. now owns 56,241 shares of the company’s stock worth $1,030,000 after purchasing an additional 25,689 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Amylyx Pharmaceuticals by 5.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 387,620 shares of the company’s stock worth $5,706,000 after purchasing an additional 21,758 shares during the period. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

(Get Free Report)

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

Featured Articles

Analyst Recommendations for Amylyx Pharmaceuticals (NASDAQ:AMLX)

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.